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atrunculin-A is a drug that is capable of rapidly, reversibly and
specifically disrupting the actin cytoskeleton1. The efficacy of its
action has made it a compound of choice in many cell-biology
laboratories, supplanting the classic actin-depolymerizing drug
cytochalasin-D. One reason for this is that the mode of action of
latrunculin seems to be less complex than that of cytochalasin.
Whereas the latter affects the kinetics of actin-filament polymeriza-
tion at both the barbed and pointed ends, latrunculin-A seems to
associate only with actin monomers, thereby preventing them from
repolymerizing into filaments2. The association of latrunculin with
monomeric, rather than filamentous, actin gave us the opportunity
to further our understanding of this interaction by detailed struc-
tural analysis of actin monomers using crystallographic techniques.
Here we show the first high-resolution structure of an actin-dis-
rupting drug in association with actin and discuss how its interac-
tions with actin, and the conformational changes that its binding
causes, may explain its mode of action within the cell.
Latrunculin (Fig. 1a) is purified from Latrunculia magnificans, a
Red Sea sponge that exudes a noxious, red fluid that kills fish within
minutes3. Two related compounds, latrunculin-A and latrunculin-
B, isolated from the fluid were shown to depolymerize actin struc-
tures both in vitro and in vivo1,4. The in vitro studies showed that
latrunculin binds only to the actin monomer and that the kinetics
of this interaction are consistent with the complex being unable to
polymerize2. Unlike cytochalasin, latrunculin can disrupt the actin
cytoskeleton in yeast cells. This has enabled genetic studies to be
carried out that have facilitated the identification of point muta-
tions in the actin gene that cause cells to become resistant to the
effects of the drug5 (Fig. 1b). The mutations that give rise to latrun-
culin resistance were found to be clustered around a distinct site,
close to the nucleotide-binding site, which indicated that they
might identify a potential binding site for latrunculin. However, as
this site is not close to recognized subunit contacts in the filament,
or to known binding sites for other proteins that associate with
actin, the mechanism by which latrunculin exerts its effects has
remained unclear.
Actin has never been known to crystallize in the absence of a bind-
ing protein that keeps it in a monodispersed state. Of the three
known examples of such binding proteins, profilin is inappropriate
as it promotes nucleotide exchange, whereas deoxyribonuclease1
binds to domains that have been implicated, in studies of yeast genet-
ics, in latrunculin binding. In contrast, gelsolin domain 1 in complex
with actin6 leaves these domains free and also reduces nucleotide
exchange, as does latrunculin. We therefore soaked latrunculin-A
L
Figure 1 Latrunculin and actin structures. a, Chemical structure of latrunculin-A.
 b, Structure of actin. Actin domains in the crystal structure in complex with gelsolin6 
are shown in green (I), blue (II), magenta (III) and cyan (IV). Bound nucleotide is shown 
as black balls and sticks; other balls and sticks represent corresponding residues 
from mutant yeast actins that are resistant to latrunculin. Diagrams were produced 
using Molscript13, Bobscript14 and Raster3D15. c, Holmes’ fit of the actin crystal 
structure to an X–ray diagram of polymeric actin16. For clarity, only one strand is 
shown, concentrating on one subunit (coloured) and showing its relation to other 
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brief communicationsinto crystals of actin in complex with gelsolin domain 1. Difference
mapping and subsequent crystallographic refinement of the model
revealed the binding site (Fig. 2a), located above the actin nucleotide-
binding site in a cleft between subdomains II and IV. 
Specific contacts (such as hydrogen bonds) are formed at the
Y69 site in subdomain II, at the T186 and R210 sites in subdomain
IV and at the D157 site in subdomain III (Fig. 2b). The 2-thiazolid-
inone group, which is rare in biology, fits neatly into a pocket and
every polar latrunculin atom, except the O2-ester oxygen, forms a
hydrogen bond with actin. These findings indicate that latrunculin
may act to prevent dissociation of the nucleotide buried in the cleft
by bridging subdomains II and IV.
The structure shows the validity of the genetic approach of map-
ping yeast mutants resistant to latrunculin onto the structure of
Figure 2 Crystal structure of the latrunculin–actin complex. a, Simulated annealing 
omit map showing electron density, at 2.5 r.m.s. deviation from the mean, for 
latrunculin A close to, but not in contact with, ATP (spacefilling). b, Stereodiagram 
showing hydrogen bonding between latrunculin A and actin. The final model consisted 
of 4182 non–hydrogen atoms with r.m.s. deviation from ideal geometry of 0.019 Å 
for bond distances and 2.4° for bond angles, with Rcryst = 0.22 and Rfree = 0.28 for all 
data. Latrunculin is shown as a semi–transparent ball–and–stick model, labelled in 
italics, with carbon atoms in grey. Every residue in actin contributing at least one 
hydrogen bond is shown, labelled with the residue name. ATP is shown as a wire–
frame skeleton for reference. W, water molecule bridging positions D214 in actin and 
O1 in latrunculin. The actin main–chain trace is shown in yellow. c, Comparison of the 
conformations of latrunculin-complexed (red) and uncomplexed (transparent) actin. 
Latrunculin is shown both as a black, ball-and-stick model and as a semi–transparent, 
space–filling model. Two conformations of the N59 site are shown, one clashing with 
the latrunculin model in the uncomplexed conformation and the other in its new 
position in the complex. Positions 197 and 207 are marked with transparent spheres. 
These delimit a large change in the loop between them. The salt bridge between the 
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brief communicationsactin. One mutation, D157E (ref. 7) is at a residue that forms a
direct hydrogen bond with latrunculin. Although it is a conserva-
tive change, glutamate cannot be accommodated without steric
clash. Other latrunculin-resistant mutants (Fig. 1b) map to the
binding site5, although none of the sites at which substitution of a
charged residue for alanine confers resistance bind directly to
latrunculin. However, these mutations are likely to affect residues
that do. Furthermore, none of these alanine mutations mapped to
subdomain II, possibly because no charged residue in this domain
is close to the binding site.
A further significant feature of the latrunculin–actin complex
structure is the strong positive density around a salt bridge between
the D187 and R206 sites. Although neither residue is directly
involved in binding to latrunculin-A, R206, which is normally
accessible at the subunit interface, is buried in the latruculin–actin
complex. The importance of the R206 site has also been shown in
yeast-actin alanine-scan studies, in which mutations of residues
including R206 caused a dominant lethal phenotype in cells8. The
D187–R206 salt bridge allows compensation of a charge that may
otherwise inhibit latrunculin binding. 
Changes in actin structure upon latrunculin binding are limited
to specific regions, rather than affecting the entire structure (Fig.
2c). In other actin structures, the two actin domains rearticulate9,
but here, the unliganded and liganded structures superpose well
(0.34-Å r.m.s. deviation of main-chain atoms of core residues). The
superposed structures (Fig. 2c) clearly show, however, that the N59
site in the unliganded structure occupies the same space as latrun-
culin does in the liganded structure. Upon latrunculin binding, the
N59 site moves out of the way and there is a local rearrangement of
the loop between the G55 and T66 sites in subdomain II. In addi-
tion, the loop between the G197 and E207 sites (subdomain IV) also
moves (Fig. 2b), possibly as a result of the 2.4-Å movement of the
first carbon atom of R206 as its sidechain forms the salt bridge.
This first picture of an actin toxin bound in situ indicates that
latrunculin may act by interfering with conformational changes
that are necessary for polymerization. First, the structure shows that
occupation of the latrunculin–binding site clamps ATP in its buried
site by preventing movement between subdomains II and IV. Sec-
ond, our structure shows that the two loops, G55 to T66 and G197
to E207, the movement of which accommodates latrunculin bind-
ing, propagate to the subunit–subunit interface at the tops of sub-
domains II and IV. In monomeric actin, these loops are among the
most mobile, and dominant and partially dominant mutations are
found within each, as shown by the alanine-scanning study5. Mod-
els of actin-filament structure predict that, upon incorporation into
a filament, these loops become more ordered at the interface with
the next subunit above. The structure shows that latrunculin bind-
ing to actin monomer exploits the very mobility of the loops,
thereby influencing distant, critical subunit contacts, at a minimal
penalty to its own binding at the better-ordered base of the cleft.
Although it is conceivable that the gelsolin domain may prevent
further conformational changes, we suggest that this is unlikely and
that our structure provides a good model for the G-actin–latruncu-
lin complex. Like latrunculin, gelsolin also limits nucleotide
exchange, and in gelsolin–actin complex, domains I and III have the
same disposition as in an actin–deoxyribonuclease1 complex, in
which these domains are unconstrained. We therefore propose that
the toxin acts as a wedge that restricts the rotation of subdomains II
and IV that is necessary for polymerization.
A further finding from the structural analysis is that the latrun-
culin-A hydrocarbon chain from C5 to C7 is exposed to solvent,
thus forming few contacts with actin. Interestingly, latrunculin-B,
but not Latrunculin-A, is found in sponges isolated near the Gulf of
Eilat1. Latrunculin-B only differs from latrunculin-A in that it lacks
two carbons in the macrocyle ring that form one of its ethylene
links. Our model is consistent with the idea that both compounds
bind in similar ways. This idea is further supported by work on bud-
ding yeast, in which cells expressing mutant actins resistant to
latrunculin-A have also been found to be resistant to latrunculin-B
(K.R.A., unpublished observations). Thus, we now have clues as to
where combinatorial chemistry may be applied to latrunculin to
derive more specific actin-binding drugs.
An understanding of the mechanism of action for commonly
used drugs is vital to facilitate interpretation of data in systems as
complicated as a eukaryotic cell. Here we present the first high-res-
olution structure of actin in association with latrunculin and pro-
pose a mechanism of action on the basis of conformational changes
induced by latrunculin binding. h
Methods
Rabbit-muscle actin and recombinant human gelsolin domain 1 were purified, complexed and 
crystallized as described10. Gelsolin domain 1–actin crystals were soaked in a nominal 5-mM latrunculin-
A solution at 4 °C for 4 h with mother liquor supplemented with 10%(v/v) DMSO, 20%(v/v) ethanol and 
25%(v/v) glycerol. Data were obtained to 2.0 Å at 100 K at beam line PX9.6 at the Daresbury synchrotron, 
UK. Coordinates that had been refined against native data collected at 100 K at DESY, Hamburg (beam 
line X11) were used as a starting model. The liganded structure was refined with REFMAC11 and 
SHELXL12.
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